GLP-1 medications have fundamentally changed what's possible in non-surgical weight loss. For decades, the options were limited: diet and exercise, or bariatric surgery. Semaglutide — the active ingredient in Ozempic and Wegovy — sits in between, producing clinical trial results that were previously only achievable through surgical intervention. If you've been struggling with weight that hasn't responded to lifestyle changes, here's what the evidence actually says.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a synthetic molecule that mimics and extends the action of glucagon-like peptide-1, a hormone your small intestine naturally releases after eating. GLP-1's job is to signal fullness to the brain, slow gastric emptying, and suppress appetite. In someone with obesity or metabolic syndrome, this hormone system is often underactive — meaning the signal comes too late, too weakly, or for too short a duration after meals.

A weekly semaglutide injection maintains that fullness signal continuously for seven days. The result: reduced appetite, significantly lower caloric intake, and meaningful body weight reduction when combined with lifestyle changes.

Semaglutide was originally developed by Novo Nordisk and approved for type 2 diabetes management as Ozempic in 2017. The weight loss benefits were so significant that a higher-dose formulation (2.4 mg weekly) received separate FDA approval as Wegovy in 2021 for chronic weight management.

Wilding JPH et al. "Once-weekly semaglutide in adults with overweight or obesity." NEJM 2021;384:989–1002. (STEP 1 trial: 14.9% body weight reduction at 68 weeks.)

View NEJM STEP 1 Trial →

What the Clinical Evidence Shows

The STEP 1 clinical trial — the landmark study that established semaglutide's weight loss efficacy — enrolled 1,961 adults with obesity (BMI ≥30, or ≥27 with a weight-related condition) and randomized them to 2.4 mg semaglutide weekly vs. placebo over 68 weeks. The results were decisive:

For context: a 200-pound person losing 14.9% of body weight is a loss of approximately 30 pounds. These are results that most patients have never achieved with diet and exercise alone, even after sustained effort over months or years.

Semaglutide vs. Tirzepatide — Which Is Better?

Tirzepatide (Mounjaro, Zepbound) is the newer alternative, approved for obesity in 2023. Where semaglutide activates one hormone pathway (GLP-1), tirzepatide activates two (GLP-1 + GIP), producing approximately 21% average weight loss in the SURMOUNT-1 trial — meaningfully more than semaglutide.

For most patients starting GLP-1 therapy at Solace, Dr. Flávio recommends beginning with semaglutide. It has the longer track record (more published safety data), a lower monthly cost, and produces excellent results for the large majority of patients. Tirzepatide is the appropriate choice when maximum weight loss is the goal, when a patient has plateaued on semaglutide, or when metabolic markers suggest the dual GIP/GLP-1 mechanism will provide additional benefit.

See the full comparison: Semaglutide vs. Tirzepatide — Which Is Right for You?

What to Expect: Side Effects and Tolerability

The side effect profile of semaglutide is well-characterized after nearly a decade of clinical use. The most common effects are gastrointestinal — nausea, constipation, and occasional diarrhea — driven by the GLP-1 mechanism that slows gastric emptying. These effects are most pronounced in the first few weeks of treatment and after dose increases, and typically improve significantly after the first 4 to 8 weeks as the body adjusts.

The most important factor in managing side effects is dose escalation protocol. Patients who start at the lowest dose (0.25 mg weekly) and increase slowly over 16 to 20 weeks experience significantly fewer and milder GI symptoms than patients who rush to higher doses. At Solace, Dr. Flávio uses a conservative titration schedule that prioritizes tolerability — the goal is steady progress, not maximum dose as fast as possible.

The Solace Medical Weight Loss Protocol

Semaglutide at Solace is administered as part of a supervised medical weight loss program — not simply a prescription and a shipping label. The protocol includes:

  1. Initial labs: Comprehensive metabolic panel, lipid profile, thyroid function, and a baseline weight assessment before any medication is started.
  2. Custom dose titration: Starting at 0.25 mg weekly, escalating gradually based on your response and tolerability — typically reaching 1.0–2.4 mg over 16–20 weeks.
  3. Monthly check-ins: Progress review, dose adjustment, and side effect management with Dr. Flávio at each milestone.
  4. Nutritional guidance: Habits and meal composition coaching that amplifies what the medication does — not a rigid diet plan, but practical adjustments that work alongside reduced appetite.
  5. Optional add-ons: Metabolic peptides (AOD-9604, CJC-1295/Ipamorelin), NAD+ injections, and hormone optimization can be integrated for patients with specific metabolic or hormonal concerns alongside weight.
  6. Maintenance phase: A structured transition to minimum effective dosing as you approach goal weight — protecting results long-term rather than abruptly stopping medication.

Semaglutide starts at $299/month at Solace. This includes medication, syringes, and provider oversight.

Who Is a Good Candidate?

FDA criteria for Wegovy-indication semaglutide: BMI ≥30, or BMI ≥27 with at least one weight-related health condition (type 2 diabetes, hypertension, high cholesterol, sleep apnea, cardiovascular disease). Most insurance plans cover it inconsistently for weight loss specifically; compounded semaglutide is significantly more accessible cost-wise and uses the same active ingredient.

Semaglutide is not appropriate for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Dr. Flávio reviews your full medical history at the initial consultation.

Frequently Asked Questions

How much weight can I expect to lose?

Clinical trials show an average of 14.9% body weight loss on semaglutide (2.4 mg weekly) at 68 weeks — roughly 30 pounds for a 200-pound person. Individual results vary: some patients lose more, particularly those who make meaningful dietary changes alongside the medication; others respond more modestly. The most important predictor of outcome is consistency with the protocol — patients who maintain their injection schedule and manage dose escalation properly achieve the best results.

What side effects should I expect?

The most common side effects are gastrointestinal — nausea (especially in the first few weeks and after dose increases), constipation, and occasional diarrhea. These are driven by the GLP-1 mechanism that slows gastric emptying. Most patients find these effects manageable and significantly better after the first month. Eating smaller portions, avoiding high-fat meals around injection day, and staying hydrated all help. Dr. Flávio's conservative dose escalation protocol minimizes early GI effects for most patients.

Do I have to inject myself?

Yes — semaglutide is a once-weekly subcutaneous injection that you self-administer at home. The pen device is designed for ease of use: cap removed, dialed to the correct dose, pressed against the skin of the abdomen, thigh, or upper arm, and the button held for six seconds. The needle is very fine and short — most patients describe the injection as barely perceptible. Dr. Flávio or Solace staff walk through the technique at your first appointment until you're comfortable.

What happens if I stop taking semaglutide?

Studies consistently show that most patients regain approximately two-thirds of lost weight within one year of stopping GLP-1 medications without a maintenance plan. This reflects the chronic nature of obesity as a hormonal and metabolic condition — the same reason that blood pressure medication needs to be continued to keep blood pressure controlled. At Solace, the program includes a structured maintenance phase: as you approach your goal, Dr. Flávio works with you to find the minimum effective maintenance dose that sustains your results rather than abruptly stopping.